Abby R Rosenberg1, Mary Tabacchi1, Kenneth H Ngo2, Michael Wallendorf3, Ilana S Rosman1,4, Lynn A Cornelius1, Shadmehr Demehri2. 1. Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. 2. Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 3. Division of Biostatistics and. 4. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Abstract
BACKGROUND:Topical calcipotriol plus 5-fluorouracil (5-FU) combination is an effective immunotherapy against actinic keratosis (AK), which is a precursor to squamous cell carcinoma (SCC). However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention is unknown. METHODS: We performed a blinded prospective cohort study on participants of a randomized double-blind clinical trial in which a 4-day course of topical calcipotriol plus 5-FU combination was compared to Vaseline plus 5-FU (control) for AK treatment. SCC and basal cell carcinoma (BCC) incidences were assessed at 1, 2, and 3 years after trial. Tissues were analyzed for calcipotriol plus 5-FU-induced T cell immunity in the skin. RESULTS:Calcipotriol plus 5-FU-induced tissue-resident memory T (Trm) cell formation in face and scalp skin associated with significantly higher erythema scores compared with control (P < 0.01). Importantly, more participants in the test cohort remained SCC-free over the more than 1,500-day follow-up period (P = 0.0765), and significantly fewer developed SCC on the treated face and scalp within 3 years (2 of 30 [7%] versus 11 of 40 [28%] in control group, hazard ratio 0.215 [95% CI: 0.048-0.972], P = 0.032). Accordingly, significantly more epidermal Trm cells persisted in the calcipotriol plus 5-FU-treated face and scalp skin compared with control (P = 0.0028). There was no significant difference in BCC incidence between the treatment groups. CONCLUSION: A short course of calcipotriol plus 5-FU treatment on the face and scalp is associated with induction of robust T cell immunity and Trm formation against AKs and significantly lowers the risk of SCC development within 3 years of treatment. FUNDING: This research was supported by internal academic funds and by grants from the Burroughs Wellcome Fund, Sidney Kimmel Foundation, Cancer Research Institute, and NIH.
RCT Entities:
BACKGROUND: Topical calcipotriol plus 5-fluorouracil (5-FU) combination is an effective immunotherapy against actinic keratosis (AK), which is a precursor to squamous cell carcinoma (SCC). However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention is unknown. METHODS: We performed a blinded prospective cohort study on participants of a randomized double-blind clinical trial in which a 4-day course of topical calcipotriol plus 5-FU combination was compared to Vaseline plus 5-FU (control) for AK treatment. SCC and basal cell carcinoma (BCC) incidences were assessed at 1, 2, and 3 years after trial. Tissues were analyzed for calcipotriol plus 5-FU-induced T cell immunity in the skin. RESULTS:Calcipotriol plus 5-FU-induced tissue-resident memory T (Trm) cell formation in face and scalp skin associated with significantly higher erythema scores compared with control (P < 0.01). Importantly, more participants in the test cohort remained SCC-free over the more than 1,500-day follow-up period (P = 0.0765), and significantly fewer developed SCC on the treated face and scalp within 3 years (2 of 30 [7%] versus 11 of 40 [28%] in control group, hazard ratio 0.215 [95% CI: 0.048-0.972], P = 0.032). Accordingly, significantly more epidermal Trm cells persisted in the calcipotriol plus 5-FU-treated face and scalp skin compared with control (P = 0.0028). There was no significant difference in BCC incidence between the treatment groups. CONCLUSION: A short course of calcipotriol plus 5-FU treatment on the face and scalp is associated with induction of robust T cell immunity and Trm formation against AKs and significantly lowers the risk of SCC development within 3 years of treatment. FUNDING: This research was supported by internal academic funds and by grants from the Burroughs Wellcome Fund, Sidney Kimmel Foundation, Cancer Research Institute, and NIH.
Entities:
Keywords:
Adaptive immunity; Cancer immunotherapy; Dermatology; Oncology; Skin cancer
Authors: Gary L Clayman; J Jack Lee; F Christopher Holsinger; Xian Zhou; Madeleine Duvic; Adel K El-Naggar; Victor G Prieto; Evelyn Altamirano; Susan L Tucker; Sara S Strom; Margaret L Kripke; Scott M Lippman Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: Dan F Spandau; Roy Chen; Jeffrey J Wargo; Craig A Rohan; David Southern; Angela Zhang; Mathew Loesch; Jonathan Weyerbacher; Sunil S Tholpady; Davina A Lewis; Matthew Kuhar; Kenneth Y Tsai; Amber J Castellanos; Michael G Kemp; Michael Markey; Elizabeth Cates; Amy R Williams; Christina Knisely; Sabina Bashir; Ryan Gabbard; Robert Hoopes; Jeffrey B Travers Journal: J Clin Invest Date: 2021-10-01 Impact factor: 14.808
Authors: Ananth Annapragada; Andrew Sikora; Catherine Bollard; Jose Conejo-Garcia; Conrad Russell Cruz; Shadmehr Demehri; Michael Demetriou; Levon Demirdjian; Lawrence Fong; Mary Horowitz; Alan Hutson; Kathryn Kadash-Edmondson; Donald Kufe; Steven Lipkin; Song Liu; Claire McCarthy; Martin Morgan; Zachary Morris; Yang Pan; Marcelo Pasquini; Stephen Schoenberger; Eliezer Van Allen; Eduardo Vilar; Yi Xing; Wenjuan Zha; Adekunle Odunsi Journal: J Immunother Cancer Date: 2020-06 Impact factor: 13.751
Authors: Timothy C Frommeyer; Craig A Rohan; Dan F Spandau; Michael G Kemp; Molly A Wanner; Elizabeth Tanzi; Jeffrey B Travers Journal: Front Oncol Date: 2022-01-07 Impact factor: 6.244